Novel hysterectomy surgical closure device seeking EU clinical trial partners

09.04.2019Published 242 days ago
Commercial
BOUS20190409001
Offers
The company offers a medical device for laparoscopic hysterectomy (i.e., minimally invasive removal of the uterus by surgery including small ports in the abdomen).

US based company treating osteoarthritis by a disease modifying drug, undergoing phase 3 clinical trials, is looking for a partnership in EU to share the final development activities and risk, as well as the subsequent sale or licensing profits

09.04.2019Published 242 days ago
Commercial
BOUS20190409002
Offers
This Pennsylvania, USA small startup pharmaceutical company is developing a new treatment for treating osteoarthritis (OA). It is poised to be the first disease-modifying product on the market, relieves pain, and increases function. The company founders and principals are seasoned pharmaceutical executives, entrepreneurs, and scientists with decades of drug development experience. OA is a leading cause of disability in persons over 60 years of age. It is characterized by chronic pain and stiffness in the joints, particularly the knee, hip, back, shoulder and hands.